United States · Bill · HR
H.R. 2044 (105th)
To suspend temporarily the duty on the production of anti-cancer drugs.
Introduced
25 June 1997
Last action
2 July 1997 · Referred
Status
See H.R.2622.
Sponsors
Rep. Matsui, Robert T. [D-CA-3]
Subjects
Discovery layer
Source updated
7 February 2024
Summary
Amends the Harmonized Tariff Schedule of the United States to suspend, through December 31, 2000, the duty on (3S)-2,2-dimethyl-3- thiomorpholine carboxylic acid (anti-cancer drug).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 June 1997
Introduced
Referred to the House Committee on Ways and Means.
Source: IntroReferral
25 June 1997
Introduced
Introduced in House
Source: IntroReferral
25 June 1997
Introduced
Introduced in House
Source: IntroReferral
2 July 1997
Committee
See H.R.2622.
Source: Committee
2 July 1997
Referred
Referred to the Subcommittee on Trade.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 25 June 1997 · Official file
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 25 June 1997
Introduced in House (PDF)
Introduced in House · EN · 25 June 1997
Introduced in House
summary · EN · 25 June 1997
Sponsors
- Rep. Matsui, Robert T. [D-CA-3] · D · Sponsor
- · hswm00 · Standing
Related records
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/105th-congress/house-bill/2044
- Open data entity: https://api.congress.gov/v3/bill/105/hr/2044
- us · 105-hr-2044 · source updated 7 February 2024